The main cause of delay in outsourced R&D projects is usually not bench execution. It starts earlier: a briefing that describes the method, but not the decision the experiment must enable.
The myth of "send the order and we will execute"
The common belief is that outsourcing preclinical R&D works like buying an off-the-shelf service: you specify the assay, the partner executes, the report is delivered on time. In practice, projects that are delayed or need to be redone rarely fail at the bench. The problem usually appears before it, in a scope that describes the desired method without explaining the decision it must enable.
A request like "we need a permeability assay in Caco-2" arrives with the model already chosen, but without saying whether the goal is initial screening, mechanistic validation or preparation for a regulatory dossier. These are three different questions, with different experimental designs, and only one usually justifies the requested model.
Before choosing between suppliers, it is worth asking what decision this experiment must enable. It is the briefing, not the commercial proposal, that determines whether this decision will be well informed.
What every preclinical R&D briefing must answer
Before specifying a method, the briefing must make five things clear:
- The scientific question the experiment must answer, not just the imagined method to reach it.
- The decision point. Does this experiment lead to a go/no-go, to the next development milestone, or to supporting data for regulatory submission? The success criterion changes according to the answer.
- What already exists. Previous data, discarded hypotheses, assays already run, including those that failed. Omitting negative results is usually the most common way to end up paying twice for the same experiment.
- Real constraints. Deadline until the next decision, available sample amount, budget. "As soon as possible" and "whatever is possible" do not replace these numbers.
- The expected delivery format. Raw data for publication, a structured report for a regulatory dossier, or direct support for an internal portfolio decision are different products, with different documentation and traceability requirements.
Signs of an incomplete briefing
Some patterns repeat in scopes that need to be redone or renegotiated mid-project:
- Specifies the method before the scientific question it must answer.
- Does not mention previous data, positive or negative, on the same candidate.
- Does not define a clear success criterion; phrases like "see how the candidate behaves" do not work as a measurable outcome.
- Treats the experimental model as fixed even when the business decision is still open.
- Does not differentiate data for internal use from data for regulatory submission.
Choosing an experimental model because it seems more complete, or simply repeating what the last partner delivered, without explaining what question it must answer, is as problematic as choosing the cheapest path without considering the candidate's biology. Both mistakes cost the same: pipeline time.
Criteria for choosing the right partner
With the briefing defined, choosing a partner stops being about the service portfolio and starts being about how they handle the question you brought.
Technical depth above the service list
Any laboratory lists "permeability assays" or "analytical validation" in a catalog. What differentiates them is whether the team reviewing your briefing can discuss experimental design and suggest adjustments before even quoting the project.
Communication in real cadence, not only in the final report
R&D projects generate intermediate decisions: an unexpected result, greater variability than predicted, a milestone that changes priority. A partner that only communicates at final delivery transfers all that risk to you.
Flexibility to design, not only to execute
A good partner questions the briefing when it does not make sense for the described question, even suggesting a different model from the one requested, when justifiable.
Regulatory compliance from the experimental design
If there is a chance the data will feed an ANVISA, FDA or EMA dossier in the future, traceability and method validation (ICH Q2, for example) must be in the design from the start. Reconstructing compliance after the experiment rarely works.
Turnaround time (TAT) aligned with your decision schedule
Competitive turnaround does not always mean faster. It means being aligned with the moment the business decision must be made. A result ten days faster does not help if your next portfolio meeting is in two months; a result ten days slower can cost an entire milestone if it is not.
Synthesis
The briefing is usually treated as the form that opens an outsourced R&D project, but in practice it works as its first deliverable. A scope that describes the decision to be made, and not just the imagined method, separates a project that moves forward on the first attempt from one that returns for reformulation after weeks at the bench.
Ready to structure the briefing for your next preclinical R&D project?